GC Green Cross said on May 2 that cumulative production of its flu vaccine exceeded 200 million doses last month. As one dose can vaccinate one adult once, this means that 200 million people around the world have been vaccinated with the GC Green Cross flu vaccine.
GC Green Cross reached the 100 million dose milestone in domestic sales last year and became the first Korean vaccine manufacturer to sell 200 million doses of flu vaccines at home and abroad.
GC Green Cross began exporting flu vaccines in 2010, one year after the product was launched. So far, it has exported the vaccines to 45 countries around the world. In particular, the company increased exports to the southern hemisphere, which has the opposite seasons as Korea, and expanded the once seasonal flu vaccine business into a year-round production system.
GC Green Cross has ranked first for the sixth time in flu vaccine bids by the Pan American Health Organization (PAHO), one of the world's largest vaccine buyers. In a recent medication bidding in the southern hemisphere, the company succeeded in earning a flu vaccine order worth US$35.7 million.
A GC Green Cross official said, "We are increasing our competitiveness both in domestic and export areas through the establishment of an optimized production system, including securing of fertile eggs throughout the year. As a company’s flu vaccine technology improves in proportion to its production volume, we will solidify our position as a global vaccine maker by targeting new markets."